Virtual Patients...Real Results

Entelos is a life sciences company improving human health through predictive biosimulation. Using in silico disease models and a virtual patient approach, Entelos identifies and validates targets, develops biomarkers, improves the success rates of clinical trials, and helps bring therapeutics to market faster.
News Releases  » Media Coverage  » Events  »
Entelos Announces U.S. Patent for Gene Expression Test for Liver Toxicity Screening - July 10
Entelos Announces DrugMatrix Perpetual License Agreement with Lilly - July 10
Trading Statement - July 10
For information on Entelos toxicogenomics solutions including DrugMatrix® and ToxFX™, please visit the Iconix website.
Game of Hearts - Condé Nast Portfolio, July 16, 2008
For more information on Entelos' research project with David Ewing Duncan, please go to www.MyDigitalHealth.com.
Pfizer Enters into Research Consortium to Expand Understanding of Diabetes and Obesity Pathobiology - Pfizer Press Release, April 25, 2008
Over here and doing well - Investors Chronicle, January 29, 2008
Lhasa Symposium / New Horizons in Toxcity Prediction - Cambridge, England
December 8

Visit Realab™, Entelos' online simulation tool.
Copyright© 2008 Entelos, Inc. All rights reserved Disclaimer (U.S. Visitors)